Industry
Life Sciences
Patient-centered Care Models Taking Center Stage in Life Sciences
Highlights
- Healthcare marketing is moving from campaigns to connected customer experiences.
- AI is shifting the conversation from efficiency gains to business growth.
- Hybrid talent and integrated delivery are becoming competitive differentiators.
- TCS Interactive's climb into MM+M's Top 10 signals the rise of a new agency model.
On this page
On this pageinpage
The paradigm shift
The future of healthcare marketing will not be defined by creativity alone, nor by technology in isolation. It will be shaped by organisations that can seamlessly combine both to deliver measurable business value. As pharmaceutical companies navigate tighter budgets, stricter regulatory scrutiny, and increasingly fragmented customer journeys, marketers are under pressure to prove impact while accelerating speed, personalisation, and innovation.
This convergence of creative thinking, data intelligence, and technology-led transformation is creating a new agency paradigm. TCS Interactive Life Sciences has emerged as a leader in this space, as this hybrid approach has helped TCS climb to seventh place on MM+M's 2026 Agency 100 ranking. The annual MM+M Awards recognise and celebrate creativity and effectiveness in healthcare marketing and communications, as voted on by industry peers. "We see ourselves as creative engineers and solution providers tapping directly into TCS' technology heritage and AI capabilities," says Gary Stamps, partner and creative director, TCS Interactive.
Budgetary constraints
Hybridisation has not only become TCS Interactive Life Sciences’ (ILS) operating model, but it is also the answer to the pharma industry's challenges — specifically, constant pressure on budgets and increasingly stringent regulatory environments. “TCS ILS is buffering its clients against these market shifts by making the economics work harder. When budgets are under pressure, an integrated partner is inherently more efficient than a roster of specialists - fewer handoffs, fewer redundant fees, faster cycles. The bigger buffer we offer is growth — using AI and data to unlock new business opportunities, sharpen pricing strategies and tie creative work directly to business KPIs, so marketing is defended as an investment rather than cut as a cost,” says Gary Stamps.
Traditional agencies focusing on creative execution seem to be diametrically opposite to TCS’ hybrid approach, as the tech company is known for its business-ROI focus. However, in this environment of contrasting scenarios, the challenge is being met squarely. Rajesh Kumaran, VP & business unit head, life sciences & healthcare at TCS, explains, “For the traditional agencies, this has led to brilliant individual campaigns but mostly a disconnected customer experience with the company and brand. TCS focuses on end-to-end outcome-focused customer experience transformation with a strong execution mindset”.
Going hybrid for a reason
This unified approach has allowed TCS to secure highly competitive enterprise-level accounts within the LS sector. In fact, very few client needs fall solely within one discipline, and few competitors can credibly address all of them under one roof.
According to Gary, “Our new business wins, whether Agency of Record (AOR) or project-based, can be attributed directly to our hybrid way of working. The work we do is creative-led, elevated with technology and data, and paired with deep life sciences and healthcare expertise. That’s why our recent wins span creative, analytics, product modernisation, content supply chain, websites, and Medical, Legal and Regulatory-heavy engagements.”
AI is genuinely transforming how marketers reach healthcare professionals and patients, but it is in the development phases — discovery, define, and ideation. Research and analysis that once took weeks can now take days, or even hours. According to Gary, AI is used extensively to review and synthesise research and data, create computer images, storyboard, generate multiple versions and quickly visualise creative directions — and to automate derivative content, freeing teams from lower-value executional work. It allows them to do considerably more in less time ultimately, reducing their T2M — time to market.
Unlocking business value
Despite a historical aversion to risk, life sciences companies are now exploring the benefits of advanced initiatives such as digital twins and AI personas. The focus has shifted from understanding the technology to understanding its impact—how it can unlock growth opportunities, strengthen pricing strategies, and translate creative investments into measurable business value.
Gary cites the case of a successful medtech engagement, building an integrated print and digital ecosystem around a robotics-assisted spine care platform, spanning brochure, web and mobile AR experiences. Another success story was a product modernisation program that consolidated fragmented brand websites and apps onto a common platform.
The winning formula
Beyond establishing itself in the top tier, TCS ILS achieved significant growth in a single year– revenue climbed from $302 million to $391 million, and its headcount expanded from 5,259 to 7,336 employees. Gary explains that the three-pronged approach helped. “First, hiring for hybrid profiles — people who combine life sciences domain expertise with creative or technical skills. Second, aggressive investment in training: more than 300,000 people across TCS have been trained as AI specialists. Third, standardising how creative, technology, data and domain teams work together.”
That big leap with AI
Across TCS broadly, the ambition is clear: to become the world’s largest AI-led technology services company. The leadership has been explicit that AI is not a replacement for human creative talent but rather a productivity tool that removes lower-value executional work, allowing people to spend more time on ideas. “It’s our ability to bring creative ideas, technical capability, AI fluency and deep industry knowledge together under the same roof that earns us the larger, enterprise-level engagements. The relationship is moving from an agent to a partner — and larger deals follow naturally from that,” concludes Gary.